Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Haematological malignancies

2593 - Tumor gene expression signatures of BCR/PI3K dependence in association with copanlisib monotherapy activity in heavily pretreated patients with indolent NHL and follicular lymphoma

Date

11 Sep 2017

Session

Haematological malignancies

Topics

Lymphomas

Presenters

Li Liu

Citation

Annals of Oncology (2017) 28 (suppl_5): v355-v371. 10.1093/annonc/mdx373

Authors

L. Liu1, K. Köchert2, H. Seidel3, J. Garcia-Vargas4, B.H. Childs5, G. Follows6, K. Bouabdallah7, M. Dreyling8, C. Peña1

Author affiliations

  • 1 Biomarker Strategy, Bayer HealthCare Pharmaceuticals, 07981 - Whippany/US
  • 2 Clinical Statistics, Bayer AG, Berlin/DE
  • 3 Bioinformatics, Bayer AG, Berlin/DE
  • 4 Clinical Development, Bayer HealthCare Pharmaceuticals USA, 07981 - Whippany/US
  • 5 Clinical Development, Bayer HealthCare Pharmaceuticals, Whippany/US
  • 6 Department Of Haematology, Cambridge University Hospitals NHS Foundation Trust Addenbrooke's Hospital, Cambridge/GB
  • 7 Service D'hématologie Et De Thérapie Cellulaire, University Hospital of Bordeaux, Pessac/FR
  • 8 Medizinische Klinik Und Poliklinik Iii, Klinikum der Universität München-Grosshadern, Munich/DE
More

Resources

Abstract 2593

Background

Copanlisib, a novel class I PI3K inhibitor with predominant activity against α and δ isoforms, has shown robust single agent anti-tumor activity in a phase 2 study in heavily pretreated patients with indolent NHL (iNHL) and follicular lymphoma (FL) (NCT01660451; Part B), with response rates of 59.6% and 58.7%, respectively. Baseline tumor gene expression profiling (GEP) was performed to confirm if gene signatures identified in patients with indolent or aggressive NHL (NCT01660451; Part A) are molecular determinants for copanlisib antitumor activity in Part B.

Methods

Signaling pathway gene sets (n = 33) were ranked by enrichment analysis (GSEA) for association with objective response based on normalized enrichment score (NES) and false discovery rate (FDR) q values. The association of weighted gene-expression score (WGS, reflecting the overall expression level for each gene set) with response was analyzed by logistic regression.

Results

Seventy-one patients with iNHL, including 54 FL, had both response data and evaluable gene expression data. All 5 gene sets reflecting upregulated PI3K/BCR signaling were top-ranked for association with higher response rates in iNHL (GSEA NES ≥ 1.93, FDR q 

Conclusions

Tumor gene expression profiling demonstrates that up-regulation of the BCR/PI3K pathway is frequent and dominant in iNHL and FL, and is associated with the high and durable copanlisib responses. These findings are consistent with copanlisib’s mode of action and strongly support the rationale for treatment of iNHL and FL patients with copanlisib.

Clinical trial identification

NCT01660451; Part B

Legal entity responsible for the study

Bayer AG

Funding

Bayer AG

Disclosure

L. Liu: Employee: Bayer HealthCare Pharmaceuticals. K. Köchert, H. Seidel: Employee: Bayer AG. J. Garcia-Vargas, B.H. Childs, C. Peña: Employment: Bayer HealthCare Pharmaceuticals. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.